M&A Deal Summary |
|
|---|---|
| Date | 2019-06-04 |
| Target | Cordlife Group |
| Sector | Healthcare Services |
| Buyer(s) | Global Cord Blood |
| Deal Type | Add-on Acquisition |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 2006 |
| Sector | Life Science |
| Employees | 1,202 |
| Revenue | 1.2B CNY (2022) |
Global Cord Blood is a provider of umbilical cord blood storage and ancillary services. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. Global Cord Blood was founded in 2006 and is based in Hong Kong, China.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector (Healthcare Services) | 1 of 1 |
| Type (Add-on Acquisition) | 1 of 2 |
| Country (Singapore) | 1 of 1 |
| Year (2019) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-04-29 |
Cellenkos
Houston, Texas, United States Cellenkos is a clinical-stage biotechnology company focused on the development and commercialization of Allogeneic, Tissue-Targeted, Immune T-Regulatory Cell Therapies to Treat Autoimmune Diseases and Inflammatory Disorders. Being derived from umbilical CB. Cellenkos' Tregs are naïve, bonafide suppressor cells that resolve inflammation through multiple direct and indirect interactions. The company utilizes its proprietary CRANETM platform technology to isolate, activate, enrich and expand the tissue-directed CB Treg cells that leverage cellular intelligence to seek, localize, proliferate and resolve tissue inflammation. Cellenkos' in-house cGMP facility allows for large-scale manufacturing where multiple doses can be generated from a single CB unit. These off-the-shelf allogeneic cell products are cryopreserved and are available on-demand for infusion at the point of care. Cellenkos is based in Houston, Texas. |
Buy | $664M |
